Fibrous dysplasia is a bone disorder in which normal bone is gradually replaced by a mix of fibrous tissue and poorly formed, immature bone. It develops because of a genetic mutation that occurs randomly during fetal development, not one inherited from a parent. The condition ranges from a single quiet lesion discovered by accident on an X-ray to widespread skeletal involvement with hormonal complications. Because it sits on such a wide spectrum, two people with the same diagnosis can have radically different experiences.
What Happens Inside the Bone
Healthy bone constantly remodels itself: old bone is broken down and replaced by organized, strong new bone. In fibrous dysplasia, the cells responsible for building bone (osteoblasts) do not mature properly. Instead of laying down well-organized bone tissue, they produce woven bone surrounded by a fibrous stroma that expands within the marrow cavity.1PubMed Central. Immature fibrous dysplasia: a mixed radio-opaque radiolucent lesion The result is bone that looks full on imaging but is structurally weaker than the real thing. These lesions can expand the bone from the inside, sometimes causing visible swelling or deformity, and they predispose the affected area to fracture under loads that healthy bone would handle easily.
The Genetic Root
Fibrous dysplasia traces back to mutations in a gene called GNAS, which encodes a signaling protein involved in how cells respond to hormones. The mutation locks that protein into an “always on” position, flooding affected cells with a chemical messenger called cyclic AMP. This overactive signaling is what drives the abnormal bone formation.2PubMed Central. Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone The mutation happens after conception, during embryonic development, so only a fraction of the body’s cells carry it. This is why fibrous dysplasia is described as a mosaic condition: some tissues have the mutation and others do not. The extent of the disease depends on when the mutation occurs and how far the affected cells spread as the embryo grows.3PubMed Central. McCune-Albright syndrome
Because it is not inherited, fibrous dysplasia does not run in families and cannot be passed to children. Studies looking for the GNAS mutation in lesion tissue find it in roughly half to over 90 percent of cases, depending on how sensitive the detection method is.4PubMed Central. GNAS Mutations in Fibrous Dysplasia: A Comparative Study of Standard Sequencing and Locked Nucleic Acid PCR Sequencing on Decalcified and Nondecalcified Formalin-fixed Paraffin-embedded Tissues The wide range reflects how thinly the mutant cells can be scattered in a tissue sample, making them easy to miss with older genetic tests.
Monostotic Versus Polyostotic Disease
Most people with fibrous dysplasia have the monostotic form, meaning only a single bone is involved. Common sites include the ribs, the skull and facial bones, and the upper thigh bone (proximal femur). The lesion often stops expanding after puberty, and many people go their whole lives without knowing they have it until a fracture or an unrelated scan reveals the abnormal bone.
The polyostotic form affects multiple bones and tends to be more disabling. Lesions typically appear in childhood and can cause progressive deformity, limping, and recurrent fractures. Pain is more common and more severe in polyostotic disease, and the condition overlaps with broader syndromes when tissues outside the skeleton are also affected.5PubMed Central. Pain in fibrous dysplasia: relationship with anatomical and clinical features
McCune-Albright Syndrome and Mazabraud Syndrome
When the GNAS mutation affects not just bone but also skin and hormone-producing glands, the condition is called McCune-Albright syndrome. Its classic features are polyostotic fibrous dysplasia, irregular light-brown skin patches (cafĂ©-au-lait spots with jagged “coast of Maine” borders), and precocious puberty, where children begin showing signs of sexual development years earlier than expected.6PubMed Central. Potent constitutive cyclic AMP-generating activity of XLαs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone Other endocrine glands can also be involved. Excess thyroid hormone speeds up metabolism; excess growth hormone drives further expansion of craniofacial lesions and can worsen skeletal deformity.7Endocrine Reviews. Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation Managing the hormonal side of McCune-Albright syndrome is not optional: uncontrolled endocrinopathies make the bone disease worse.
A rarer association is Mazabraud syndrome, in which fibrous dysplasia coexists with soft-tissue myxomas, benign jelly-like tumors that form inside muscles. It shares the same underlying GNAS mutation.8PubMed Central. Mazabraud’s Syndrome – A Diagnosis Commonly Missed Myxomas are painless lumps and, on their own, are harmless. The clinical significance of Mazabraud syndrome lies mostly in avoiding a misdiagnosis: a soft-tissue mass near a bone lesion in someone with fibrous dysplasia should raise suspicion for a myxoma, not a malignancy.
How Fibrous Dysplasia Is Diagnosed
Imaging is usually the first step. On plain X-rays, a typical fibrous dysplasia lesion appears as a well-defined area of hazy, “ground-glass” density inside the bone.9Applied Radiology. Craniofacial Fibrous Dysplasia That ground-glass look is the hallmark: it results from the mixture of woven bone and fibrous tissue replacing normal marrow. Not every lesion looks the same, though. Some are mostly see-through (radiolucent), others are dense and white (sclerotic), depending on how much woven bone is present versus fibrous tissue.
CT scanning is preferred for craniofacial lesions because it shows the anatomy in more detail and helps determine whether the lesion is encroaching on important structures like the optic nerve or sinuses.10PubMed Central. Fibrous dysplasia for radiologists: beyond ground glass bone matrix MRI is sometimes added to evaluate soft-tissue involvement or complications. When a biopsy is performed, the tissue under the microscope shows irregularly shaped trabeculae of woven bone, often compared to “Chinese characters,” surrounded by a bland fibrous background with no rim of mature osteoblasts lining the bone surfaces.11Libre Pathology. Fibrous dysplasia That absence of osteoblastic rimming is one of the key microscopic features that helps pathologists distinguish fibrous dysplasia from similar-looking conditions.
One condition frequently confused with fibrous dysplasia is ossifying fibroma, a benign tumor of the jawbones. The two can look alike on both imaging and biopsy, and distinguishing them requires combining clinical, radiographic, and microscopic findings.12PubMed Central. Fibrous Dysplasia versus Juvenile Ossifying Fibroma: A Dilemma A key practical difference is that ossifying fibroma is a discrete, well-encapsulated tumor that is typically excised, whereas fibrous dysplasia blends into surrounding bone and tends to be managed more conservatively.
The Phosphate Problem
Beyond the local effects on bone, fibrous dysplasia can cause a systemic problem: abnormal phosphorus handling. The abnormal bone cells overproduce a hormone called FGF23, which tells the kidneys to dump phosphate into the urine.13PubMed Central. Fibrous dysplasia and fibroblast growth factor-23 regulation In patients with enough disease burden, this leads to low blood phosphate levels, a state called hypophosphatemia. Phosphate is essential for mineralizing bone properly, so losing it through the kidneys compounds the bone weakness that already exists from the lesion itself. In a study of fibrous dysplasia patients, FGF23 levels correlated with disease burden and bone turnover markers, and were significantly higher in those with measurable phosphate wasting than in those without it.14JCI Insight. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
Low serum phosphorus is not just a lab curiosity. Research has linked it to worse skeletal outcomes, including a higher risk of deformity in weight-bearing bones.15PubMed Central. Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia For patients with polyostotic disease, checking phosphorus and FGF23 levels is an important part of routine monitoring. When phosphate is low enough to contribute to bone softening, supplementation with phosphorus and active vitamin D can help, though it requires careful dosing and follow-up.
Treatment of Bone Pain
Pain is one of the most common reasons people with fibrous dysplasia seek treatment, and its severity tracks with how widespread the disease is. Bisphosphonates, drugs originally developed for osteoporosis, are the primary medical therapy. They work by suppressing bone turnover, which in fibrous dysplasia is abnormally high. In a long-term study of intravenous pamidronate, pain intensity dropped significantly, bone turnover markers fell, and roughly half of patients showed improvement on follow-up imaging, with previously see-through lesions filling in or cortical bone thickening.16PubMed. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment Zoledronic acid, a more potent bisphosphonate, has shown similar benefits. In a small series, six of seven patients reported partial or complete pain relief, and a key marker of bone breakdown dropped by about 60 percent after treatment.17PubMed Central. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience
Bisphosphonates improve symptoms and lab values, but they have not been proven in rigorous trials to prevent fractures or halt disease progression in fibrous dysplasia. They are used pragmatically because the alternatives are limited, and the pain relief they provide is real and meaningful for many patients.
Newer Drug Approaches
Denosumab, a drug that blocks the signaling pathway responsible for activating bone-resorbing cells, is being explored as an alternative to bisphosphonates. An early case report in a child with aggressive, expanding fibrous dysplasia showed dramatic reduction in pain, bone turnover markers, and lesion growth over seven months of treatment.18PubMed Central. Denosumab treatment for fibrous dysplasia A subsequent phase 2 clinical trial reported profound reductions in lesion activity and increased mineralization of the abnormal bone after six months of high-dose therapy.19PubMed Central. Safety and Efficacy of Moderate-dose Denosumab in Fibrous Dysplasia: Observational Results From a Phase 2 Clinical Trial These results are encouraging, but denosumab is not yet a standard treatment for fibrous dysplasia, and more data on long-term safety and efficacy are needed. One practical concern with denosumab is rebound: when the drug is stopped, bone turnover can surge, so careful monitoring during and after discontinuation is important.
When Surgery Is Needed
Surgery enters the picture for fractures, progressive deformity, or when expanding bone threatens a critical structure. One of the most common surgical scenarios involves the proximal femur. A classic deformity called the “shepherd’s crook” develops when recurrent fractures and abnormal bone cause the upper femur to bow into a curved shape. Correcting it usually requires cutting the bone (osteotomy), realigning it, and stabilizing it with hardware like an intramedullary nail or angled blade plate.20PubMed Central. Individualized approach to the surgical management of fibrous dysplasia of the proximal femur For complex deformities combining severe coxa vara (a steep angle of the upper femur) with shaft bowing, staged procedures may be needed.21PubMed Central. Surgical treatment of femoral deformities in polyostotic fibrous dysplasia and McCune-Albright syndrome: A literature review
Bone grafting is sometimes used to fill defects after surgery, but results are mixed. A study of polyostotic patients who received bone grafts found that the graft survived about 50 percent of the time at roughly 14 and a half years. Grafts placed in older patients (average age around 21) lasted much better than those placed in younger patients (average age around 10), likely because younger patients still have actively growing and expanding disease.22PubMed Central. Bone-Grafting in Polyostotic Fibrous Dysplasia Neither allograft nor autograft showed a clear advantage. The takeaway for patients and families is that bone grafting in growing children with active disease carries a real risk of graft resorption and may need to be repeated.
In the skull and face, surgery is sometimes considered when fibrous dysplasia encases the optic nerve, raising concern about vision loss. However, a meta-analysis found that most patients with radiographic evidence of optic nerve encasement remain asymptomatic. Surgical decompression is best reserved for those who actually develop visual symptoms, where it tends to produce good results. For asymptomatic patients, regular eye exams and imaging follow-up are the recommended approach.23PLoS ONE. Surgery versus Watchful Waiting in Patients with Craniofacial Fibrous Dysplasia – a Meta-Analysis
Malignant Transformation
One of the most common fears people with fibrous dysplasia voice is whether their lesion can become cancerous. The risk exists, but it is very low. Malignant transformation is estimated to occur in well under 1 percent of cases over a lifetime. A review of ten patients whose monostotic fibrous dysplasia did transform found that the most frequently affected bones were the femur and tibia. Half of those patients had undergone prior surgery at the site, but none had received radiation therapy.24PubMed Central. Malignant transformation in monostotic fibrous dysplasia: clinical features, imaging features, outcomes in 10 patients, and review The historical association between radiation and sarcoma arising in fibrous dysplasia is why radiation is avoided as a treatment for this condition. Any sudden increase in pain, rapid enlargement of a known lesion, or cortical destruction on imaging should prompt urgent evaluation to rule out transformation.
Living with Fibrous Dysplasia
Because fibrous dysplasia is a chronic condition with no cure, quality of life matters as much as any lab value. A Dutch study found that patients scored significantly lower than the general population on nearly every physical domain of a standard quality-of-life questionnaire. The mental health domain, though, was largely preserved, suggesting that emotional well-being holds up even when physical function does not. Quality of life tracked closely with disease burden: patients with more extensive skeletal involvement and higher bone turnover markers fared worse.25PubMed Central. Determinants of impaired quality of life in patients with fibrous dysplasia A separate study from the same research group found that how patients perceived their illness, specifically the emotional weight they attached to it and the consequences they anticipated, predicted quality of life above and beyond the physical measures.26PubMed Central. Illness Perceptions are Associated with Quality of Life in Patients with Fibrous Dysplasia That finding underscores the value of psychological support, not just orthopedic and endocrine care, for people managing this condition over decades.
Blood-Based Genetic Testing
Confirming a GNAS mutation has traditionally required a tissue biopsy, which is invasive and does not always catch the mutation because of its mosaic nature. Newer liquid biopsy techniques look for fragments of the mutant gene floating in the blood. In a study of 66 patients, researchers detected the GNAS mutation in circulating cell-free DNA in about two-thirds of cases using sensitive PCR-based methods. Combining two different assay techniques pushed the detection rate to roughly 68 percent.27PubMed. Identification of GNAS Variants in Circulating Cell-Free DNA from Patients with Fibrous Dysplasia/McCune Albright Syndrome An earlier, smaller study using a slightly different approach found mutant DNA in the blood of about 80 percent of tested patients when using circulating cell-free DNA specifically.28PubMed. Using Digital Droplet Polymerase Chain Reaction to Detect the Mosaic GNAS Mutations in Whole Blood DNA or Circulating Cell-Free DNA in Fibrous Dysplasia and McCune-Albright Syndrome These are not perfect numbers, and a negative blood test does not rule out the diagnosis. Still, being able to confirm the genetic basis without surgery is a meaningful advance, especially for patients with lesions in locations where biopsy carries higher risk, such as the skull base.
Pregnancy and Hormonal Fluctuations
Fibrous dysplasia lesions are generally thought to stabilize or slow down after skeletal maturity, but hormonal surges can reactivate them. Pregnancy is the most dramatic example. A case report described a teenager who had no known history of fibrous dysplasia until pregnancy triggered a sudden, symptomatic flare of the disease.29Journal of Adolescent Health. Exacerbation of fibrous dysplasia associated with an adolescent pregnancy Growth hormone excess, as seen in some McCune-Albright patients, is another hormonal driver. A study of craniofacial lesions found that patients with growth hormone excess had faster rates of lesion expansion.30PubMed. Lesion Expansion in Craniofacial Fibrous Dysplasia: Natural History and Indicators of Progression in the Frontal, Zygomatic, and Sphenoid Bones These observations reinforce why endocrine management in McCune-Albright syndrome is not a separate problem from the bone disease; the two are intertwined. For women with known fibrous dysplasia who are considering pregnancy, discussing the potential for disease flare with a specialist beforehand is a reasonable step.